Загрузка...
Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia
Ibrutinib and idelalisib are kinase inhibitors that have revolutionized the treatment of chronic lymphocytic leukemia (CLL). Capable of inducing durable remissions, these agents also modulate the immune system. Both ibrutinib and idelalisib abrogate the tumor-supporting microenvironment by disruptin...
Сохранить в:
| Опубликовано в: : | Leuk Lymphoma |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6237652/ https://ncbi.nlm.nih.gov/pubmed/29764250 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2018.1457147 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|